[Combination chemotherapy with cis-platinum, vinblastine and adriamycin for non-small cell lung cancer].
A combination chemotherapy consisting of cis-platinum (CDDP), vinblastine (VLB) and adriamycin (ADM) was given to fourteen patients with non-small cell lung cancer. The treatment consisted of CDDP 60 mg/m2 i.v., divided over two days (on days 1 and 2) or five days (on days 1-5), and VLB 3.5 mg/m2 and ADM 40 mg/m2 i.v. on day 1 and repeated every four weeks. Of fourteen evaluable patients, there were two with partial responses (14%), eleven with no change and one with progressive disease. The durations of the partial responses were 3 and 4 months, respectively. The median time to disease progression in the patients with partial response plus no change was 6 months. The median survival time of all treated patients was 13.5 months. Leukopenia of less than 2,000/mm3 was seen in 36% and decreased hemoglobin of more than 1 g/dl in 50%. Mild transient renal dysfunction was observed in 7%, cumulative renal dysfunction in 29%, alopecia in 100%, nausea and vomiting in 93% and peripheral neuropathy in 43%. We conclude that a combination chemotherapy with CDDP, VLB and ADM has moderate activity against non-small cell lung cancer.
Ito
Y
Y
Dept. of Medical Oncology, Cancer Institute Hospital.
Ogawa
M
M
Horikoshi
N
N
Inoue
K
K
Mukaiyama
T
T
Imajou
K
K
Ozeki
H
H
Nagamine
D
D
Shinagawa
K
K
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D014747:Vinblastine / Q000008:administration & dosage
D014747:Vinblastine; D004317:Doxorubicin; D002945:Cisplatin